Abstract
The introduction of human papillomavirus vaccine (HPV) into practice in 2006 has resulted in a general increase in interest in this sexually transmitted infection. The public and the public have become aware of the fact that HPV is a sexually transmitted infection with high prevalence, which in its persistence threatens men, women and children.
After 10 years of onset of vaccination, a non-vaccine vaccine has been introduced into clinical practice, which significantly increases the effectiveness of vaccination and already has population data confirming its meaning and safety. Since the discovery of HPV in 1907, more than half a century has passed since 1974-1984 proved prof.
Zur Hausen, the causal link between HPV infection and cervical cancer, for which he received the Nobel Prize in 2008. The knowledge of this causal link was the basis for the development of HPV vaccines in 2006 (Quadrivalent Silgard(R), HPV 6/11/16/18), 2007 (Cervarix(R) bivalent vaccine, HPV 16/18) and 2015 (nonavalent vaccine Gardasil(R)9, HPV 6/11/16/18/31/33/45/52/58) are included in clinical use if the World Health Organization recommends relying on any newly established screening of cervical cancer screening to detect the presence of HPV.